Beyond the Class Effect — Does Beta-Blocker Choice Matter after Myocardial Infarction?

“some heterogeneity may exist and is likely related to geographical and pharmacologic differences - with the Scandinavian trials, predominantly using metoprolol, tending to show more favourable results than southern European studies, where bisoprolol was commonly prescribed.”

“The study presents important results that update and refine cardiovascular pharmacotherapy and underline how important it is not to assume that drugs in the same class will have identical activities and clinical indications”

“To be honest, I don't think anyone can claim to know the absolute truth here, because it's still an open issue.”